Testicular, Penile, and Rare Malignancies
Advertisement
Drs. Necchi and Tawagi highlight some the challenges in penile cancer, including "suboptimal" neoadjuvant, adjuvant options.
Paclitaxel, ifosfamide, and cisplatin is a combination commonly used for the treatment of germ cell tumors.
A recent dose-escalation study has demonstrated the safety and efficacy of cabo/nivo or cabo/nivo/ipi for several GU cancers.
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
A recent trial provides the first evidence of efficacy from ICIs in PSCC with a manageable safety profile.
The SWENOTECA cancer care program sought to evaluate survival, toxicity in patients treated with HDCT from 2011 through 2021.
A study to determine the potential utility of ADCs targeting TROP-2 in both localized PSCC and distant metastases.
Dr. Spiess highlights prevalence of TERT expression and an increase in TROP-2 mRNA expression levels in PSCC patients.
The primary end point was establishing the risk of relapse connected with both surgical approaches.
Dr. Mollica continues her discussion on prognostic factors and clinical outcomes in PSCC.
Dr. Mollica highlights her recent research investigating prognostic factors and clinical outcomes for patients with PSCC.
The IGCCCG was used to compare the survival probabilities of patients with testicular GCTs with or without teratoma.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
While most STMs are benign, between 13% and 21% are malignant, and distinguishing between them remains a challenge.
Research into the potential benefits of ctDNA for patients with testicular cancer both before and after diagnosis is lacking.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Survivors with high CIPN experienced more side effects compared to those with low CIPN.
Drs. Ambinder and Elsamra explore robotic surgery, including its applicability, patient benefits, and evolving role.
The Meet-URO 23/I-RARE registry hosts data from patients with rare genitourinary malignancies.
We spoke with clinicians about some of the disparities that exist, why they persist, and what might be done to correct them.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.